Angiotensin II analogue

Generic Name: Angiotensin II analogue

Clinical Trials

Phase 2 Study of TXA127 in Post-ischemic Stroke Patients

Phase 2

Recruiting

Conditions: Ischemic Stroke

Interventions: Drug: talfirastide
Drug: Placebo

First Posted Date: 2023-11-18

Last Posted Date: 2023-12-21

Lead Sponsor: Constant Therapeutics LLC

Target Recruit Count: 50

Registration Number: NCT06135103

Locations: 🇮🇱
Sheba Medical Center, Ramat Gan, Israel

TXA127 in Non-Ambulant Patients With DMD Cardiomyopathy

Phase 2

Recruiting

Conditions: DMD-Associated Dilated Cardiomyopathy

Interventions: Drug: talfirastide

First Posted Date: 2023-08-28

Last Posted Date: 2024-01-23

Lead Sponsor: Constant Therapeutics LLC

Target Recruit Count: 10

Registration Number: NCT06013839

Locations: 🇮🇱
Sheba Medical Center, Ramat Gan, Israel
🇮🇱
Hadassah Medical Center, Jerusalem, Israel

Novel Experimental COVID-19 Therapies Affecting Host Response

Phase 2

Completed

Conditions: COVID-19
SARS-CoV-2 Infection
Coronavirus Infection

Interventions: Drug: TXA127
Drug: Placebo
Drug: TRV027
Drug: Fostamatinib

First Posted Date: 2021-06-14

Last Posted Date: 2025-01-22

Lead Sponsor: Sean Collins

Target Recruit Count: 1060

Registration Number: NCT04924660

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Ponce de Leon Clinical Research Site, Atlanta, Georgia, United States
🇺🇸
Emory St. Joseph's Hospital, Atlanta, Georgia, United States

and more 48 locations

TXA127 for the Treatment of Severe COVID-19

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: TXA127
Drug: Placebo

First Posted Date: 2020-05-26

Last Posted Date: 2022-07-27

Lead Sponsor: Columbia University

Target Recruit Count: 22

Registration Number: NCT04401423

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation

Phase 2

Withdrawn

Conditions: Hematologic Malignancies

Interventions: Drug: TXA127

First Posted Date: 2013-06-20

Last Posted Date: 2016-08-31

Lead Sponsor: Tarix Pharmaceuticals

Registration Number: NCT01882374

Locations: 🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States

Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Phase 2

Withdrawn

Conditions: Hematologic Malignancies

Interventions: Drug: TXA127

First Posted Date: 2013-06-20

Last Posted Date: 2016-08-31

Lead Sponsor: Tarix Pharmaceuticals

Registration Number: NCT01882387

Locations: 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸
Siteman Cancer Center, St Louis, Missouri, United States

Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation

Phase 2

Withdrawn

Conditions: Cord Blood Transplant
Hematologic Malignancy
Inherited Metabolic Disease

Interventions: Drug: TXA127

First Posted Date: 2012-03-14

Last Posted Date: 2016-08-31

Lead Sponsor: Tarix Pharmaceuticals

Registration Number: NCT01554254

Locations: 🇺🇸
Pediatric Bone and Cord Blood, Duke Univ. Med. Center, Durham, North Carolina, United States

Safety and Efficacy of TXA127 and Neupogen to Increase Peripheral Blood Stem Cells (PBSCs)

Phase 1

Completed

Conditions: Miscellaneous Peripheral Blood Cell Abnormalities

Interventions: Drug: TXA127
Drug: Neupogen (filgrastim)

First Posted Date: 2012-03-05

Last Posted Date: 2016-08-31

Lead Sponsor: Tarix Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT01543971

Locations: 🇺🇸
Charles River Clinical Servies Norhtwest, Tacoma, Washington, United States

Phase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia

Phase 1

Terminated

Conditions: Myelodysplastic Syndrome (MDS)

Interventions: Drug: TXA127

First Posted Date: 2011-05-27

Last Posted Date: 2016-08-31

Lead Sponsor: Tarix Pharmaceuticals

Target Recruit Count: 2

Registration Number: NCT01362036

Locations: 🇺🇸
MD Anderson Leukemia Department, Houston, Texas, United States

Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients

Phase 2

Terminated

Conditions: Lymphoma, Non-Hodgkin
Hodgkin Disease
Multiple Myeloma

Interventions: Drug: TXA127
Drug: Placebo

First Posted Date: 2010-05-12

Last Posted Date: 2020-12-08

Lead Sponsor: Tarix Pharmaceuticals

Target Recruit Count: 75

Registration Number: NCT01121120

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
City of Hope Hospital, Duarte, California, United States

and more 7 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy